San Diego-based mostly Viking Therapeutics marked alone as a serious competitor within the weight loss drug current market in February immediately after revealing promising data from a mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented being a weekly injection and in March